FDA Expands Eplontersen (Wainua) to hATTR Cardiomyopathy: A New Era in Cardiac Amyloid Treatment

Why Does Silencing TTR Production Matter for Cardiac Amyloidosis Patients?

Hereditary transthyretin amyloid cardiomyopathy arises when genetically variant transthyretin protein, produced primarily by the liver, misfolds and deposits as amyloid fibrils within the myocardium. Over time, this infiltration stiffens the ventricular walls, impairs diastolic filling, and leads to progressive heart failure. The disease affects an estimated several thousand patients worldwide who carry pathogenic TTR gene mutations, with Val122Ile being notably prevalent among individuals of African descent.

Eplontersen's antisense mechanism works at the messenger RNA level inside hepatocytes. Conjugation with a triantennary N-acetylgalactosamine (GalNAc) ligand enables efficient receptor-mediated uptake by liver cells, where the drug hybridizes with TTR mRNA and triggers its degradation via RNase H1. Clinical data from the eplontersen development program have consistently demonstrated approximately 80–85% reductions in circulating TTR protein. By drastically lowering the supply of the precursor protein, this approach aims to halt further amyloid deposition and potentially allow the body's natural clearance mechanisms to gradually remove existing cardiac amyloid burden.

How Does the CARDIO-TTRansform Approval Change the Treatment Landscape for hATTR-CM?

Prior to eplontersen's cardiac indication, tafamidis (Vyndaqel/Vyndamax) was the only FDA-approved pharmacotherapy specifically for ATTR cardiomyopathy. Tafamidis works by binding to circulating TTR tetramers and preventing their dissociation into amyloid-forming monomers — a stabilization approach demonstrated to reduce mortality and hospitalization in the landmark ATTR-ACT trial. However, tafamidis does not reduce TTR protein levels, and some patients continue to progress despite treatment. Eplontersen offers a complementary mechanism by eliminating TTR production rather than stabilizing it.

In the CARDIO-TTRansform trial, eplontersen-treated patients maintained 6-minute walk distance and showed more favorable trajectories in NT-proBNP — a biomarker of cardiac wall stress — compared to placebo recipients who experienced the expected deterioration. The monthly self-injection via autoinjector also addresses practical barriers to care, as many hATTR-CM patients are elderly and may have difficulty traveling to infusion centers. Clinicians now have the option to select therapy based on individual patient factors: disease stage, mutation type, concurrent polyneuropathy, and the desire for maximal TTR suppression versus protein stabilization. Platelet monitoring remains important, as reduced platelet counts are a recognized class effect of antisense oligonucleotides.